



FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

February 06, 2021

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

BSE Script Code: 531599

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051

NSE Symbol: FDC

Sub: Press Release

Dear Sir/Ma'am,

Please find attached herewith the Press Release issued in relation to the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter & nine months ended December 31, 2020.

Kindly take the same on record.

Thanking you,

Yours truly

For FDC Limited


Varshaarani Katre
Company Secretary
F-8948





FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

FDC Limited reports Q3FY21 results

Mumbai, 06th February, 2021: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the third quarter ending 31st Dec., 2020.

Consolidated Q3FY21 and 9MFY21 FDC reported:

Rs. in lakhs	Q3' 20-21	Q3' 19-20	YOY Growth %
Operating Revenues	34,023.03	32,122.18	5.92
EBITDA	10,877.11	11,576.01	-6.04
EBITDA %	28.98	32.86	-6.04
PBT	9,878.22	10,576.45	-6.60
PAT	7,521.34	7,414.86	1.44
EPS	4.45	4.31	3.16

Rs. in lakhs	9M' 20-21	9M' 19-20	YOY Growth %
Operating Revenues	101,980.44	101,085.96	0.88
EBITDA	36,507.75	29,479.29	23.84
EBITDA %	33.13	27.59	23.84
PBT	33,443.13	26,423.30	26.57
PAT	25,501.49	18,439.49	38.30
EPS	15.00	10.72	39.98

India Market:

Highlights:

- Q3FY21 revenue at Rs.249.85 Crore, up by 2.75% YOY
- 9MFY21 revenue at Rs. 757.44 Crore, down by 6.20% YOY

Overall sales in India markets accounted for 74% of total consolidated sales for the quarter. Anti-infective therapy market has not shown recovery yet and is having negative impact on FDC domestic sales.

Export Formulations Market:

Highlights:

- Q3FY21 revenue at Rs. 75.13 Crore, up by 15.31% YOY
- 9MFY21 revenue at Rs. 212.63 Crore, up by 31.66% YOY
- ANDA is filled for Ofloxacin Otic Solutions



CORPORATE OFFICE : 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2677 3462
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE : B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176

The main contributor is the USA market, accounting to 68.96% of total Export Formulations Sales. Dorzolamide and Timolol is expected to be commercialized in USA by 1st quarter of FY22.

To suffice the ophthalmic export order, the company is in process to expand its Production Capacity by installation of an additional BFS machine at existing plant. The Company's estimated cost towards the enhancement of production capacity would be around Rs. 74 crores at first stage and around Rs. 26 crores at later stage. The said process is spread over a period of 20 months.

The total production capacity of the said plant is likely to be increased by 30 to 33% after commissioning and completion of all the Regulatory requirements. This will help us in catering further pipeline export orders for regulated market.

Export API Market:

Highlights:

- Q3FY21 revenue at Rs. 12.66 Crore, up by 18.01 % YOY
- 9MFY21 revenue at Rs. 41.79 Crore, up by 18.19% YOY

ABOUT FDC LTD

Established in 1940, with the dream of building a world class company and vision to make the nation self-reliant in healthcare. FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE, to cite a few. FDC is a forerunner in manufacturing and marketing of Oral Rehydration Salts (ORS) and Ophthalmic. FDC has also set-up globally approved, multi-location manufacturing facilities for Active Pharmaceutical Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life to millions globally.

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

